MEOI and HRQoL in CLL Patients Treated With BTKis
Public ClinicalTrials.gov record NCT04938141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment With Bruton's Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-site observational study of medical events of interest (MEOI) and health-related quality of life (HRQoL) in chronic lymphocytic leukemia (CLL) patients initiating treatment with the Bruton's tyrosine kinase inhibitors (BTKi) acalabrutinib or ibrutinib in the United States (US)
Study identification
- NCT ID
- NCT04938141
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2021
- Primary completion
- Sep 25, 2024
- Completion
- Sep 25, 2024
- Last update posted
- May 20, 2025
2021 – 2024
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Fountain Valley | California | 92708 | — |
| Research Site | Redlands | California | 92373 | — |
| Research Site | Boca Raton | Florida | 33486 | — |
| Research Site | Fort Lauderdale | Florida | 33308 | — |
| Research Site | St. Petersburg | Florida | 33709 | — |
| Research Site | Tallahassee | Florida | 32308 | — |
| Research Site | Tamarac | Florida | 33321 | — |
| Research Site | Tampa | Florida | 33705-1407 | — |
| Research Site | Savannah | Georgia | 31405 | — |
| Research Site | Honolulu | Hawaii | 96813-5516 | — |
| Research Site | Jackson | Mississippi | 39202 | — |
| Research Site | Berkeley Heights | New Jersey | 07922 | — |
| Research Site | Amherst | New York | 14228 | — |
| Research Site | Charlotte | North Carolina | 27103 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | York | Pennsylvania | 17403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04938141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2025 · Synced Sep 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04938141 live on ClinicalTrials.gov.